• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

    4/16/25 8:00:46 AM ET
    $CDTX
    $PHAT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CDTX alert in real time by email

    FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors.

    Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions.

    "We are pleased to welcome Ted to the Phathom Board during a pivotal period for the company," said Michael Cola, Chairman of the Board, Phathom Pharmaceuticals. "Ted is a seasoned biopharma leader with a strong history of developing and commercializing innovative treatments, scaling growth-focused organizations, and creating shareholder value. As Phathom continues to unlock the full potential of VOQUEZNA®, Ted's deep operational and commercial expertise will be an important asset. We look forward to his insights and partnership as we work to accelerate our commercial momentum and deliver our first-in-class therapies to patients in need."

    About Ted Schroeder

    Mr. Schroeder served as Chief Executive Officer of Nabriva Therapeutics from 2018 to 2023 and as a director until March 2025, following Nabriva's acquisition of Zavante Therapeutics, where he was co-founder, President, and CEO. Prior to that, he co-founded Cadence Pharmaceuticals and served as President and CEO until its $1.4 billion acquisition by Mallinckrodt Pharmaceuticals in 2014. Earlier in his career, he held senior leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals, and Bristol-Myers Squibb.

    Mr. Schroeder currently serves on the Board of Directors of Cidara Therapeutics (NASDAQ:CDTX) and has previously served on the boards of several public and private life sciences companies, including Otonomy, Collegium Pharmaceutical, Hyperion Therapeutics, Incline Therapeutics, and Trius Therapeutics. He is also a former Chairman of Biocom California and the Antimicrobials Working Group. In 2014, he was named EY Entrepreneur of the Year for the San Diego region and was recognized as a national finalist.

    He holds a B.S. in Management from Rutgers University.

    About Phathom Pharmaceuticals, Inc.

    Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company's website at www.phathompharma.com follow on LinkedIn and X.

    MEDIA CONTACT

    Nick Benedetto

    1-877-742-8466

    [email protected]

    INVESTOR CONTACT

    Eric Sciorilli

    1-877-742-8466

    [email protected]

    © 2025 Phathom Pharmaceuticals. All rights reserved.

    VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.



    Primary Logo

    Get the next $CDTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDTX
    $PHAT

    CompanyDatePrice TargetRatingAnalyst
    Cidara Therapeutics Inc.
    $CDTX
    3/12/2025$46.00Mkt Outperform
    Citizens JMP
    Phathom Pharmaceuticals Inc.
    $PHAT
    2/14/2025$23.00Overweight
    Cantor Fitzgerald
    Cidara Therapeutics Inc.
    $CDTX
    1/27/2025Overweight
    Cantor Fitzgerald
    Cidara Therapeutics Inc.
    $CDTX
    12/13/2024$34.00Outperform
    RBC Capital Mkts
    Cidara Therapeutics Inc.
    $CDTX
    11/8/2024$33.00Buy
    Guggenheim
    Cidara Therapeutics Inc.
    $CDTX
    8/14/2024$24.00Neutral → Buy
    H.C. Wainwright
    Phathom Pharmaceuticals Inc.
    $PHAT
    5/3/2024$24.00Buy
    Stifel
    Phathom Pharmaceuticals Inc.
    $PHAT
    1/5/2024$23.00 → $26.00Buy
    Needham
    More analyst ratings

    $CDTX
    $PHAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and pro

      5/8/25 4:15:38 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company's Board of Directors has approved the grant of inducement awards. On May 1, 2025, the Company's Board of Directors granted inducement awards to Mr. Bentley under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Mr. Bentley was granted a non-qualified stock option to purchase 79,365 shares of Phathom common

      5/1/25 4:15:59 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that Nicole Davarpanah, M.D., J.D. has been promoted to chief medical officer (CMO), and Corrina Pavetto has been promoted to senior vice president, clinical development, effective May 1, 2025. "These promotions come at a pivotal time as we continue advancing our influenza antiviral candidate, CD388, through our Phase 2b NAVIGATE trial and plan for Phase 3," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "Nicole and Corrina have shown exceptional

      5/1/25 8:00:00 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    $PHAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Parikh Asit bought $24,984 worth of shares (10,000 units at $2.50), increasing direct ownership by 12% to 95,500 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/8/25 5:27:00 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Breedlove Robert Charles claimed ownership of 55,192 shares (SEC Form 3)

      3 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/6/25 4:59:33 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schroeder Theodore R was granted 21,000 shares (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      4/16/25 5:44:03 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDTX
    $PHAT
    Leadership Updates

    Live Leadership Updates

    See more

    $CDTX
    $PHAT
    Financials

    Live finance-specific insights

    See more

    $CDTX
    $PHAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company's Board of Directors has approved the grant of inducement awards. On May 1, 2025, the Company's Board of Directors granted inducement awards to Mr. Bentley under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Mr. Bentley was granted a non-qualified stock option to purchase 79,365 shares of Phathom common

      5/1/25 4:15:59 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

      FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions. "We are pleased to welcome Ted to the Phathom Board during a pivotal period for the com

      4/16/25 8:00:46 AM ET
      $CDTX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and pro

      5/8/25 4:15:38 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwindsStrategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commerciali

      5/1/25 7:00:41 AM ET
      $ITCI
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

      SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its first quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, May 8, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Thursday, May 8, 2025Time:5:00 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Conferen

      4/24/25 8:00:00 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Parikh Asit bought $24,984 worth of shares (10,000 units at $2.50), increasing direct ownership by 12% to 95,500 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/8/25 5:27:00 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Parikh Asit bought $44,200 worth of shares (10,000 units at $4.42), increasing direct ownership by 13% to 85,500 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      3/17/25 4:27:25 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Karbe Frank bought $99,084 worth of shares (12,500 units at $7.93), increasing direct ownership by 28% to 57,000 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      12/16/24 8:05:06 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDTX
    $PHAT
    SEC Filings

    See more
    • SEC Form S-3 filed by Cidara Therapeutics Inc.

      S-3 - Cidara Therapeutics, Inc. (0001610618) (Filer)

      5/8/25 5:25:12 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Cidara Therapeutics Inc.

      10-Q - Cidara Therapeutics, Inc. (0001610618) (Filer)

      5/8/25 4:47:25 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cidara Therapeutics, Inc. (0001610618) (Filer)

      5/8/25 4:25:37 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    $PHAT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

      Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

      7/18/24 10:52:01 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

      Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

      5/11/22 10:51:07 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

      Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

      5/11/22 10:17:03 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDTX
    $PHAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cidara Therapeutics Inc.

      SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

      12/9/24 5:37:15 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cidara Therapeutics Inc.

      SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

      12/4/24 4:15:14 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cidara Therapeutics Inc.

      SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

      12/3/24 4:34:49 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    $PHAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on Cidara Therapeutics with a new price target

      Citizens JMP initiated coverage of Cidara Therapeutics with a rating of Mkt Outperform and set a new price target of $46.00

      3/12/25 7:22:04 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Phathom Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals with a rating of Overweight and set a new price target of $23.00

      2/14/25 7:06:18 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Cidara Therapeutics

      Cantor Fitzgerald resumed coverage of Cidara Therapeutics with a rating of Overweight

      1/27/25 8:36:28 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care